NEW YORK (GenomeWeb News) – Genomic cancer diagnostic services firm Kew Group today announced it has closed a private round of financing.

The Cambridge, Mass.-based firm did not disclose the amount of the round or how it will be used, and it did not respond to an e-mail seeking comment. However, in a document filed with the US Securities and Exchange Commission earlier this moth, Kew said that it raised $16.1 million toward a targeted goal of $30.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.